U.S. News Room
October 19, 2025
DATROWAY Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Versus Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial
Download
October 19, 2025
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2,3 Trial
Download
October 19, 2025
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1,2 Trial
Download
October 18, 2025
ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial
Download